CBD and Phytocannabinoids: What You Need to Know




3 CEUs for NJ Chiropractors, NJ Physical Therapists, NJ Massage Therapists and Athletic Trainers

  • NJ Chiropractors: NJBOCE #1901-37 and PACE Program of the Federation of Chiropractic Licensing Boards
  • NJ Physical Therapists/PTAs:  NJBOPTE # 1901-42
  • Athletic Trainers – Board of Certification Approved Provider #8552
  • NJ Massage Therapists – Approved under Section 13:37-4.2(a) (i)(xiii) of the New Jersey Board of Massage and Bodywork Therapy regulations.

Location for upcoming course:

August 28 – The Institute for Continuing Education, 7 Spielman Road, Fairfield, NJ. Class: 6:00-9:00pm.

Cannabidiol (CBD) is a phytocannabinoid; a chemical constituent sourced from plants in the cannabis genus. Other phytocannabinoids include tetrahydrocannabinol (THC), cannabinol, cannabigerol, and cannabichromene. Because THC is an hallucinogenic, cannabis cultivation has been banned in the United States for a century. Recent biopharma developments in medical CBD, along with passage of federal and state regulations supporting hemp research, has spurred interest in CBD. As a topical, CBD has therapeutic properties as an anti-inflammatory, anti-nociceptive, and anti-oxidant. There are potential risks, benefits, and legal implications for healthcare professionals who are interested in using topical CBD products with clients. This workshop will introduce the endocannabinoid system, examine CBD physiology, explore factors affecting development of and access to cannabis products, compare and contrast phytocannabinoids, and summarize legal and scope-of-practice issues influencing use of topical CBD.

Workshop Objectives:

At the end of this workshop, attendees will be able to:

  • Describe the endocannabinoid system
  • Differentiate between endocannabinoids and phytocannabinoids
  • Identify the plants in the cannabis genus and species
  • Recognize the influence of historical politics on cannabis in the United States
  • Compare and contrast clinical applications of CBD and THC
  • Summarize recent research on phytocannabinoids
  • Describe factors that influence availability of topical CBD and phytocannabinoids  products
  • State resources that govern scope of practice for professional use of topical phytocannabinoids
  • Explain third party verification and its relevance to plant-based products
  • List resources to monitor changes in legal use of topical CBD in professional practice


Introductions and Agenda
Overview of the Endocannabinoid System

·         Discovery

·         Anatomy & physiology

·         Endocannabinoids

·         Fatty acid amide hydrolase (FAAH) inhibitors

·         Clinical implications


·         Marihuana, marijuana, and hemp botanical summary

·         History of cannabis in the U.S.

Phytocannabinoids and endocannabinoids

·         CBD

·         THC

·         Other cannabinoids

Research on phytocannabinoids

·         Medical CBD

·         Medical cannabis

·         CBD for wellness and consumer use

·         Challenges in cannabis research

Legal Implications for topical use

·         The 2018 Agriculture Improvement Act

·         State regulations

·         The importance of third party verification

·         Professional scope of practice


Instructor: Virginia S. Cowen, PhD is a consultant for clients in the consumer cannabis industry, and has developed graduate level Ethnomedicine and Natural Therapies curriculum and business sector workshops on The Endocannabinoid System. Dr. Cowen is also a therapeutic massage, bodywork and exercise professional with years of experience teaching and developing health curriculum at the college and post-graduate levels.

Additional information


Wednesday, August 28, 2019 6:00-9:00pm in Fairfield